- Home
- ANTX vs VRCA Comparison
ANTX vs VRCA Comparison
Compare ANTX & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- VRCA
- Stock Information
- Founded
- ANTX 2017
- VRCA 2013
- Country
- ANTX United States
- VRCA United States
- Employees
- ANTX N/A
- VRCA N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- ANTX Health Care
- VRCA Health Care
- Exchange
- ANTX Nasdaq
- VRCA Nasdaq
- Market Cap
- ANTX 37.3M
- VRCA 43.0M
- IPO Year
- ANTX 2022
- VRCA 2018
- Fundamental
- Price
- ANTX $1.20
- VRCA $0.44
- Analyst Decision
- ANTX Buy
- VRCA Hold
- Analyst Count
- ANTX 4
- VRCA 5
- Target Price
- ANTX $2.00
- VRCA $6.00
- AVG Volume (30 Days)
- ANTX 133.7K
- VRCA 237.2K
- Earning Date
- ANTX 05-16-2025
- VRCA 05-13-2025
- Dividend Yield
- ANTX N/A
- VRCA N/A
- EPS Growth
- ANTX N/A
- VRCA N/A
- EPS
- ANTX N/A
- VRCA N/A
- Revenue
- ANTX N/A
- VRCA $7,566,000.00
- Revenue This Year
- ANTX N/A
- VRCA $127.58
- Revenue Next Year
- ANTX N/A
- VRCA $88.06
- P/E Ratio
- ANTX N/A
- VRCA N/A
- Revenue Growth
- ANTX N/A
- VRCA 47.66
- 52 Week Low
- ANTX $0.87
- VRCA $0.38
- 52 Week High
- ANTX $3.07
- VRCA $11.41
- Technical
- Relative Strength Index (RSI)
- ANTX 43.48
- VRCA 44.12
- Support Level
- ANTX $1.05
- VRCA $0.39
- Resistance Level
- ANTX $1.29
- VRCA $0.48
- Average True Range (ATR)
- ANTX 0.07
- VRCA 0.05
- MACD
- ANTX -0.00
- VRCA -0.00
- Stochastic Oscillator
- ANTX 54.55
- VRCA 44.95
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.